S&P 500   4,064.08 (-0.31%)
DOW   34,369.53 (-0.07%)
QQQ   292.08 (-0.56%)
AAPL   147.20 (-0.75%)
MSFT   254.47 (-0.09%)
META   123.57 (+2.60%)
GOOGL   100.25 (-0.73%)
AMZN   94.05 (-1.52%)
TSLA   194.11 (-0.30%)
NVDA   167.91 (-2.01%)
NIO   13.12 (+8.52%)
BABA   90.40 (+5.19%)
AMD   75.28 (-2.84%)
T   18.99 (-1.04%)
MU   54.48 (-1.82%)
CGC   4.32 (+9.92%)
F   13.84 (-1.70%)
GE   86.69 (+1.68%)
DIS   99.36 (+0.78%)
AMC   8.27 (+1.22%)
PYPL   74.81 (-4.74%)
PFE   50.83 (-0.49%)
NFLX   320.67 (+1.17%)
S&P 500   4,064.08 (-0.31%)
DOW   34,369.53 (-0.07%)
QQQ   292.08 (-0.56%)
AAPL   147.20 (-0.75%)
MSFT   254.47 (-0.09%)
META   123.57 (+2.60%)
GOOGL   100.25 (-0.73%)
AMZN   94.05 (-1.52%)
TSLA   194.11 (-0.30%)
NVDA   167.91 (-2.01%)
NIO   13.12 (+8.52%)
BABA   90.40 (+5.19%)
AMD   75.28 (-2.84%)
T   18.99 (-1.04%)
MU   54.48 (-1.82%)
CGC   4.32 (+9.92%)
F   13.84 (-1.70%)
GE   86.69 (+1.68%)
DIS   99.36 (+0.78%)
AMC   8.27 (+1.22%)
PYPL   74.81 (-4.74%)
PFE   50.83 (-0.49%)
NFLX   320.67 (+1.17%)
S&P 500   4,064.08 (-0.31%)
DOW   34,369.53 (-0.07%)
QQQ   292.08 (-0.56%)
AAPL   147.20 (-0.75%)
MSFT   254.47 (-0.09%)
META   123.57 (+2.60%)
GOOGL   100.25 (-0.73%)
AMZN   94.05 (-1.52%)
TSLA   194.11 (-0.30%)
NVDA   167.91 (-2.01%)
NIO   13.12 (+8.52%)
BABA   90.40 (+5.19%)
AMD   75.28 (-2.84%)
T   18.99 (-1.04%)
MU   54.48 (-1.82%)
CGC   4.32 (+9.92%)
F   13.84 (-1.70%)
GE   86.69 (+1.68%)
DIS   99.36 (+0.78%)
AMC   8.27 (+1.22%)
PYPL   74.81 (-4.74%)
PFE   50.83 (-0.49%)
NFLX   320.67 (+1.17%)
S&P 500   4,064.08 (-0.31%)
DOW   34,369.53 (-0.07%)
QQQ   292.08 (-0.56%)
AAPL   147.20 (-0.75%)
MSFT   254.47 (-0.09%)
META   123.57 (+2.60%)
GOOGL   100.25 (-0.73%)
AMZN   94.05 (-1.52%)
TSLA   194.11 (-0.30%)
NVDA   167.91 (-2.01%)
NIO   13.12 (+8.52%)
BABA   90.40 (+5.19%)
AMD   75.28 (-2.84%)
T   18.99 (-1.04%)
MU   54.48 (-1.82%)
CGC   4.32 (+9.92%)
F   13.84 (-1.70%)
GE   86.69 (+1.68%)
DIS   99.36 (+0.78%)
AMC   8.27 (+1.22%)
PYPL   74.81 (-4.74%)
PFE   50.83 (-0.49%)
NFLX   320.67 (+1.17%)
NASDAQ:PODD

Insulet - PODD Stock Forecast, Price & News

$307.64
-0.36 (-0.12%)
(As of 12/2/2022 03:33 PM ET)
Add
Compare
Today's Range
$302.27
$308.99
50-Day Range
$212.22
$313.00
52-Week Range
$181.00
$320.00
Volume
4,307 shs
Average Volume
593,954 shs
Market Capitalization
$21.37 billion
P/E Ratio
1,281.83
Dividend Yield
N/A
Price Target
$300.62

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
2.2% Downside
$300.62 Price Target
Short Interest
Healthy
3.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.40mentions of Insulet in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$7.76 M Sold Last Quarter
Proj. Earnings Growth
1.96%
From $1.02 to $1.04 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

639th out of 1,052 stocks

Surgical & Medical Instruments Industry

69th out of 104 stocks

PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Dan Manea Sells 200 Shares of Insulet Co. (NASDAQ:PODD) Stock
Why Insulet Stock Is Skyrocketing Today
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Company Calendar

Last Earnings
11/03/2022
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,300
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$300.62
High Stock Price Forecast
$345.00
Low Stock Price Forecast
$238.00
Forecasted Upside/Downside
-2.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
14 Analysts

Profitability

Net Income
$16.80 million
Pretax Margin
1.68%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.11 per share
Book Value
$6.16 per share

Miscellaneous

Free Float
68,824,000
Market Cap
$21.37 billion
Optionable
Optionable
Beta
0.79

Social Links


Key Executives

  • Dr. James R. Hollingshead Ph.D. (Age 59)
    Pres, CEO & Director
    Comp: $69.81k
  • Mr. Wayde D. McMillan (Age 52)
    Exec. VP,CFO & Treasurer
    Comp: $946.57k
  • Mr. Charles AlpucheMr. Charles Alpuche (Age 62)
    Exec. VP & COO
    Comp: $1.03M
  • Mr. John Wodick Kapples (Age 62)
    Sr. VP & Gen. Counsel
    Comp: $783.36k
  • Ms. Shacey PetrovicMs. Shacey Petrovic (Age 48)
    Director & Advisor
    Comp: $1.72M
  • Mr. Bret ChristensenMr. Bret Christensen (Age 51)
    Exec. VP & Chief Commercial Officer
    Comp: $883.8k
  • Ms. Lauren Budden
    VP, Chief Accounting Officer & Controller
  • Ms. Deborah R. Gordon CPA (Age 52)
    VP of Investor Relations
  • Mr. Michael Spears (Age 57)
    Sr. VP of Regulatory Affairs & Compliance
  • Angela Geryak Wiczek
    Sr. Director of Corp. Communications













PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price forecast for 2023?

14 Wall Street analysts have issued 1 year price targets for Insulet's shares. Their PODD share price forecasts range from $238.00 to $345.00. On average, they expect the company's share price to reach $300.62 in the next twelve months. This suggests that the stock has a possible downside of 2.4%.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2022?

Insulet's stock was trading at $266.07 on January 1st, 2022. Since then, PODD stock has increased by 15.8% and is now trading at $308.00.
View the best growth stocks for 2022 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our PODD earnings forecast
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings data on Thursday, November, 3rd. The medical instruments supplier reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.17 by $0.28. The medical instruments supplier had revenue of $340.80 million for the quarter, compared to analysts' expectations of $311.84 million. Insulet had a trailing twelve-month return on equity of 18.19% and a net margin of 1.35%.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $341.55 million-$350.78 million, compared to the consensus revenue estimate of $328.46 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.20%), Price T Rowe Associates Inc. MD (4.70%), Primecap Management Co. CA (1.69%), Fred Alger Management LLC (0.91%), Allspring Global Investments Holdings LLC (0.77%) and Echo Street Capital Management LLC (0.71%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, Dan Manea, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $308.00.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $21.39 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.24 on an earnings per share basis.

How many employees does Insulet have?

The company employs 2,300 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 12/2/2022 by MarketBeat.com Staff